Bayer AG
BAYZF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.18T
Close$
Earnings Call Q2 2025
August 6, 2025 - AI Summary
Sales and Earnings Performance: Bayer reported flat sales growth across the group in H1 2025, with a core EPS of EUR 3.72. Free Cash Flow stood at minus EUR 1.4 billion, indicating challenges in cash generation, though the company is on track to meet its initial outlook for 2025.
Pharmaceuticals Growth Outlook: The company is raising its currency-adjusted sales and earnings guidance due to a strong performance in its Pharmaceuticals segment, driven by growth from launch assets like Nubeqa and Kerendia, which alone experienced a 65% increase year-over-year. Expectations are set for continued growth in these products, further supported by recent approvals for additional indications.
Crop Science Division Challenges: In the Crop Science division, sales remained challenged due to regulatory impacts such as the loss of dicamba and Movento registration, with expectations of a full-year margin impact of 200-300 basis points. Despite this, there are signs of recovery in Corn sales due to pricing and acreage expansion, though concerns remain about potential market headwinds.
Exclusive for Stockcircle Pro members
Sign up
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.18 Trillion |
|---|---|
| Enterprise Value | $1.17 Trillion |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -4.67% |
|---|---|
| Return on Assets | -1.20% |
| Return on Invested Capital | 6.81% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 25.37 |
| Enterprise Value to EBIT | 204.15 |
| Enterprise Value to Net Income | -858 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Bayer AG
87,830 employees
CEO: Werner Baumann
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Ani...